|
1
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu
Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet.
395:497–506. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang F, Deng L, Zhang L, Cai Y, Cheung CW
and Xia Z: Review of the clinical characteristics of coronavirus
disease 2019 (COVID-19). J Gen Intern Med. 35:1545–1549. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gavriatopoulou M, Ntanasis-Stathopoulos I,
Korompoki E, Fotiou D, Migkou M, Tzanninis IG, Psaltopoulou T,
Kastritis E, Terpos E and Dimopoulos MA: Emerging treatment
strategies for COVID-19 infection. Clin Exp Med. 21:167–179. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
World Health Organization (WHO), . WHO
Coronavirus (COVID-19) Dashboard. WHO; Geneva: 2017, https://covid19.who.int/June 17–2022
|
|
5
|
Machhi J, Herskovitz J, Senan AM, Dutta D,
Nath B, Oleynikov MD, Blomberg WR, Meigs DD, Hasan M, Patel M, et
al: The natural history, pathobiology, and clinical manifestations
of SARS-CoV-2 infections. J Neuroimmune Pharmacol. 15:359–386.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
National Institutes of Health, . COVID-19
Treatment Guidelines: Clinical Spectrum of SARS-CoV-2 Infection.
https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/June
17–2022
|
|
7
|
World Health Organization (WHO), .
Therapeutics and COVID-19: living guideline. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.4June
17–2022
|
|
8
|
Cheng Y, Luo R, Wang K, Zhang M, Wang Z,
Dong L, Li J, Yao Y, Ge S and Xu G: Kidney disease is associated
with in-hospital death of patients with COVID-19. Kidney Int.
97:829–838. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suardi LR, Pallotto C, Esperti S, Tazzioli
E, Baragli F, Salomoni E, Botta A, Frigieri FC, Pazzi M, Stera C,
et al: Risk factors for non-invasive/invasive ventilatory support
in patients with COVID-19 pneumonia: A retrospective study within a
multidisciplinary approach. Int J Infect Dis. 100:258–263. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ustun GK, Keskin A, Aci R, Erdem MA and
Ari M: Association between Hb A1c and severity of COVID-19
patients. Hemoglobin. 45:124–128. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
British Medical Journal Best Practice, .
Coronavirus disease 2019 (COVID-19): Epidemiology. Coronavirus
disease. 2019.https://bestpractice.bmj.com/topics/en-gb/3000201/epidemiologyJune
17–2022
|
|
12
|
Wu J, Hu L, Zhang G, Wu F and He T:
Accuracy of presepsin in sepsis diagnosis: A systematic review and
meta-analysis. PLoS One. 10:e01330572015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kermali M, Khalsa RK, Pillai K, Ismail Z
and Harky A: The role of biomarkers in diagnosis of COVID-19-A
systematic review. Life Sci. 254:1177882020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pan F, Yang L, Li Y, Liang B, Li L, Ye T,
Li L, Liu D, Gui S, Hu Y and Zheng C: Factors associated with death
outcome in patients with severe coronavirus disease-19 (COVID-19):
A case-control study. Int J Med Sci. 17:1281–1292. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Soraya GV and Ulhaq ZS: Crucial laboratory
parameters in COVID-19 diagnosis and prognosis: An updated
meta-analysis. Med Clin (Barc). 155:143–151. 2020.(In English,
Spanish). View Article : Google Scholar
|
|
16
|
Li J, He X, Yuan Y, Zhang W, Li X, Zhang
Y, Li S, Guan C, Gao Z and Dong G: Meta-analysis investigating the
relationship between clinical features, outcomes, and severity of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
pneumonia. Am J Infect Control. 49:82–89. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ghahramani S, Tabrizi R, Lankarani KB,
Kashani SMA, Rezaei S, Zeidi N, Akbari M, Heydari ST, Akbari H,
Nowrouzi-Sohrabi P and Ahmadizar F: Laboratory features of severe
vs. non-severe COVID-19 patients in Asian populations: A systematic
review and meta-analysis. Eur J Med Res. 25:302020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ou M, Zhu J, Ji P, Li H, Zhong Z, Li B,
Pang J, Zhang J and Zheng X: Risk factors of severe cases with
COVID-19: A meta-analysis. Epidemiol Infect. 148:e1752020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Elshazli RM, Toraih EA, Elgaml A,
El-Mowafy M, El-Mesery M, Amin MN, Hussein MH, Killackey MT, Fawzy
MS and Kandil E: Diagnostic and prognostic value of hematological
and immunological markers in COVID-19 infection: A meta-analysis of
6320 patients. PLoS One. 15:e02381602020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Danwang C, Endomba FT, Nkeck JR, Wouna
DLA, Robert A and Noubiap JJ: A meta-analysis of potential
biomarkers associated with severity of coronavirus disease 2019
(COVID-19). Biomark Res. 8:372020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Paparella D, Colucci M, Squiccimarro E,
Raimondo P, De Palma F, Ranieri P, Mariggiò MA and Grasso S:
Clotting abnormalities in critically ill COVID-19 patients are
inconsistent with overt disseminated intravascular coagulation.
Thromb Res. 196:272–275. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mehta AA, Haridas N, Belgundi P and Jose
WM: A systematic review of clinical and laboratory parameters
associated with increased severity among COVID-19 patients.
Diabetes Metab Syndr. 15:535–541. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yitbarek GY, Ayehu GW, Asnakew S, Ayele
FY, Gare MB, Mulu AT, Dagnaw FT and Melesie BD: The role of
C-reactive protein in predicting the severity of COVID-19 disease:
A systematic review. SAGE Open Med. 9:205031212110507552021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bivona G, Agnello L and Ciaccio M:
Biomarkers for prognosis and treatment response in COVID-19
patients. Ann Lab Med. 41:540–548. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adachi M, Murakami M, Yoneoka D, Kawashima
T, Hashizume M, Sakamoto H, Eguchi A, Ghaznavi C, Gilmour S, Kaneko
S, et al: Factors associated with the risk perception of COVID-19
infection and severe illness: A cross-sectional study in Japan. SSM
Popul Health. 18:1011052022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamamoto A, Wada H, Ichikawa Y, Mizuno H,
Tomida M, Masuda J, Makino K, Kodama S, Yoshida M, Fukui S, et al:
Evaluation of biomarkers of severity in patients with COVID-19
infection. J Clin Med. 10:37752021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang I, Pranata R, Lim MA, Oehadian A and
Alisjahbana B: C-reactive protein, procalcitonin, D-dimer, and
ferritin in severe coronavirus disease-2019: A meta-analysis. Ther
Adv Respir Dis. 14:17534666209371752020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J,
Li Y, Li T, Zhang S, Wu C, et al: C-reactive protein level may
predict the risk of COVID-19 aggravation. Open Forum Infect Dis.
7:ofaa1532020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ali N: Elevated level of C-reactive
protein may be an early marker to predict risk for severity of
COVID-19. J Med Virol. 92:2409–2411. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B
and Zhang J: Association of elevated inflammatory markers and
severe COVID-19: A meta-analysis. Medicine (Baltimore).
99:e233152020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stringer D, Braude P, Myint PK, Evans L,
Collins JT, Verduri A, Quinn TJ, Vilches-Moraga A, Stechman MJ,
Pearce L, et al: The role of C-reactive protein as a prognostic
marker in COVID-19. Int J Epidemiol. 50:420–429. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Smilowitz NR, Kunichoff D, Garshick M,
Shah B, Pillinger M, Hochman JS and Berger JS: C-reactive protein
and clinical outcomes in patients with COVID-19. Eur Heart J.
42:2270–2279. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zaninotto M, Mion MM, Cosma C, Rinaldi D
and Plebani M: Presepsin in risk stratification of SARS-CoV-2
patients. Clin Chim Acta. 507:161–163. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Endo S, Suzuki Y, Takahashi G, Shozushima
T, Ishikura H, Murai A, Nishida T, Irie Y, Miura M, Iguchi H, et
al: Usefulness of presepsin in the diagnosis of sepsis in a
multicenter prospective study. J Infect Chemother. 18:891–897.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Masson S, Caironi P, Spanuth E, Thomae R,
Panigada M, Sangiorgi G, Fumagalli R, Mauri T, Isgrò S, Fanizza C,
et al: Presepsin (soluble CD14 subtype) and procalcitonin levels
for mortality prediction in sepsis: Data from the Albumin Italian
outcome sepsis trial. Crit Care. 18:R62014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fan Z, Chen L, Li J, Cheng X, Yang J, Tian
C, Zhang Y, Huang S, Liu Z and Cheng J: Clinical features of
COVID-19-related liver functional abnormality. Clin Gastroenterol
Hepatol. 18:1561–1566. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Y, Liu S, Liu H, Li W, Lin F, Jiang
L, Li X, Xu P, Zhang L, Zhao L, et al: SARS-CoV-2 infection of the
liver directly contributes to hepatic impairment in patients with
COVID-19. J Hepatol. 73:807–816. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li J and Fan JG: Characteristics and
mechanism of liver injury in 2019 coronavirus disease. J Clin
Transl Hepatol. 8:13–17. 2020. View Article : Google Scholar : PubMed/NCBI
|
